Stay updated on Sabatolimab Combo in MDS: Clinical Trial

Sign up to get notified when there's something new on the Sabatolimab Combo in MDS: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sabatolimab Combo in MDS: Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A new revision entry, v3.5.4, is added to the record history. The prior revision v3.5.3 is removed from the list of changes.
    Difference
    0.1%
    Check dated 2026-05-15T06:53:53.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The page revision version was updated from v3.5.2 to v3.5.3, reflecting a maintenance or deployment change rather than an update to the trial record content.
    Difference
    0.1%
    Check dated 2026-04-23T21:56:21.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision entry added: v3.5.2; the previous v3.5.0 entry was removed.
    Difference
    0.1%
    Check dated 2026-04-16T12:20:26.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Revision: v3.5.0 released, replacing v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-18T21:16:16.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Added a new revision entry v3.4.3 to the study record history and removed the previous v3.4.2 entry.
    Difference
    0.1%
    Check dated 2026-03-11T17:52:38.000Z thumbnail image
  8. Check
    99 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the history, and the previous v3.4.1 funding notice has been removed.
    Difference
    0.5%
    Check dated 2026-02-11T09:20:57.000Z thumbnail image

Stay in the know with updates to Sabatolimab Combo in MDS: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sabatolimab Combo in MDS: Clinical Trial page.